Companion Animal Product & Promotions Guide

July 2020

Animal Health Solution - a Henry Schein Animal Health magazine for veterinary professionals

Issue link: https://www.e-digitaleditions.com/i/1260341

Contents of this Issue

Navigation

Page 12 of 27

When a cat's eating habits change and they are losing weight, there's no time to waste. In a recent study, a body condition score (BCS) of 6 had the highest survival probability. Lifespan decreased when cats had a BCS less than 5 out of 9. 1 Manage weight loss while you determine the cause. Mirataz ® (mirtazapine transdermal ointment) is the only FDA-approved transdermal medication for the management of weight loss in cats. Mirataz ® is a registered trademark of Dechra Ltd. Inc. © 2020 Dechra Veterinary Products. All rights reserved. 01AD-MIR50213-0520 "9 LIVES? I WISH!" Important Safety Information Mirataz ® (mirtazapine transdermal ointment) is for topical use in cats only under veterinary supervision. Do not use in cats with a known hypersensitivity to mirtazapine or any of the excipients. Do not use in cats treated with monoamine oxidase inhibitors (MAOIs). Not for human use. Keep out of reach of children. Wear gloves when handling/applying, wash hands after and avoid contact between the treated cat and people or other animals for 2 hours following application. Use with caution in cats with hepatic and kidney disease. Cat's food intake should be monitored upon discontinuation. Safety has not been evaluated in cats less than 2 kg, less than six months of age or in breeding, pregnant or lactating cats. The most common adverse reactions observed during clinical trials were application site reactions, behavioral abnormalities (vocalization and hyperactivity) and vomiting. For additional safety information, see brief summary of prescribing information on following page. Mirataz is indicated for the management of weight loss in cats. Reference: 1. Teng KT, McGreevy PD, Toribio JL, et al. Strong associations of nine-point body condition scoring with survival and lifespan in cats. J Feline Med Surg. 2018;20(12):1110-1118. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA-1088. To order, please contact your Dechra representative or call (866) 683-0660. 24-hour Veterinary Technical Support available (866) 933-2472. Nonurgent Technical Support available via email support@dechra.com. Now available from Dechra Veterinary Products! Learn more about Mirataz at www.mirataz.com.

Articles in this issue

Links on this page

Archives of this issue

view archives of Companion Animal Product & Promotions Guide - July 2020